Evotec SE Share Price Other OTC
Equities
EVTCY
US30050E1055
Biotechnology & Medical Research
Sales 2024 * | 875M 947M 78.9B | Sales 2025 * | 1.03B 1.11B 92.66B | Capitalization | 1.7B 1.84B 154B |
---|---|---|---|---|---|
Net income 2024 * | -28M -30.33M -2.53B | Net income 2025 * | 24M 25.99M 2.16B | EV / Sales 2024 * | 2.25 x |
Net Debt 2024 * | 269M 291M 24.27B | Net Debt 2025 * | 235M 255M 21.2B | EV / Sales 2025 * | 1.89 x |
P/E ratio 2024 * |
-61.3
x | P/E ratio 2025 * |
36.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.64% |
Latest transcript on Evotec SE
Managers | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Laetitia Rouxel
DFI | Director of Finance/CFO | 51 | 07/23/07 |
Craig Johnstone
COO | Chief Operating Officer | 54 | 01/12/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Mario Polywka
CEO | Chief Executive Officer | 61 | 19/19/19 |
Roland Sackers
BRD | Director/Board Member | 56 | 19/19/19 |
Chairman | 63 | 17/14/17 |
1st Jan change | Capi. | |
---|---|---|
+64.23% | 55.07B | |
-2.31% | 41.79B | |
+44.36% | 40.22B | |
-8.29% | 28.17B | |
+11.97% | 26.28B | |
-21.16% | 18.93B | |
+7.54% | 13.03B | |
+27.17% | 12.26B | |
+25.72% | 12.21B |